in my opinion, opportunity can be found at the int
Post# of 145351
in this case, the 75 non-miTT are contradictory to the miTT as well as the Agresti, Yang, and Montefiore patients.
the intersection is the 75 non-miTT patients, where probably also exists a coherent reason for the fda's lack of EUA.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)